vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Plymouth Industrial REIT, Inc. (PLYM). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $51.2M, roughly 1.7× Plymouth Industrial REIT, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -106.3%, a 129.1% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -1.4%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 0.4%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.

FDMT vs PLYM — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.7× larger
FDMT
$85.1M
$51.2M
PLYM
Growing faster (revenue YoY)
FDMT
FDMT
+8508901.4% gap
FDMT
8508900.0%
-1.4%
PLYM
Higher net margin
FDMT
FDMT
129.1% more per $
FDMT
22.8%
-106.3%
PLYM
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
0.4%
PLYM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FDMT
FDMT
PLYM
PLYM
Revenue
$85.1M
$51.2M
Net Profit
$19.4M
$-54.4M
Gross Margin
Operating Margin
17.3%
-102.5%
Net Margin
22.8%
-106.3%
Revenue YoY
8508900.0%
-1.4%
Net Profit YoY
139.1%
-248.5%
EPS (diluted)
$0.43
$-1.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
PLYM
PLYM
Q4 25
$85.1M
Q3 25
$90.0K
$51.2M
Q2 25
$15.0K
$47.2M
Q1 25
$14.0K
$45.6M
Q4 24
$1.0K
$47.6M
Q3 24
$3.0K
$51.9M
Q2 24
$5.0K
$48.7M
Q1 24
$28.0K
$50.2M
Net Profit
FDMT
FDMT
PLYM
PLYM
Q4 25
$19.4M
Q3 25
$-56.9M
$-54.4M
Q2 25
$-54.7M
$-6.1M
Q1 25
$-48.0M
$5.8M
Q4 24
$147.4M
Q3 24
$-43.8M
$-15.6M
Q2 24
$-35.0M
$1.3M
Q1 24
$-32.4M
$6.2M
Operating Margin
FDMT
FDMT
PLYM
PLYM
Q4 25
17.3%
Q3 25
-67983.3%
-102.5%
Q2 25
-396373.3%
-10.3%
Q1 25
-383007.1%
Q4 24
Q3 24
-1704400.0%
-29.6%
Q2 24
-849120.0%
2.7%
Q1 24
-136200.0%
Net Margin
FDMT
FDMT
PLYM
PLYM
Q4 25
22.8%
Q3 25
-63195.6%
-106.3%
Q2 25
-364386.7%
-12.9%
Q1 25
-342657.1%
12.8%
Q4 24
309.9%
Q3 24
-1461433.3%
-30.1%
Q2 24
-699060.0%
2.7%
Q1 24
-115717.9%
12.4%
EPS (diluted)
FDMT
FDMT
PLYM
PLYM
Q4 25
$0.43
Q3 25
$-1.01
$-1.23
Q2 25
$-0.98
$-0.14
Q1 25
$-0.86
$0.13
Q4 24
$3.24
Q3 24
$-0.79
$-0.35
Q2 24
$-0.63
$0.03
Q1 24
$-0.66
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
PLYM
PLYM
Cash + ST InvestmentsLiquidity on hand
$402.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$505.7M
$470.1M
Total Assets
$566.7M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
PLYM
PLYM
Q4 25
$402.7M
Q3 25
$305.1M
Q2 25
$293.2M
Q1 25
$321.4M
Q4 24
$424.9M
Q3 24
$501.9M
Q2 24
$541.9M
Q1 24
$525.9M
Total Debt
FDMT
FDMT
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$646.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
FDMT
FDMT
PLYM
PLYM
Q4 25
$505.7M
Q3 25
$369.0M
$470.1M
Q2 25
$420.9M
$539.6M
Q1 25
$469.7M
$571.0M
Q4 24
$510.6M
$579.5M
Q3 24
$552.9M
$436.5M
Q2 24
$588.3M
$475.2M
Q1 24
$600.6M
$484.6M
Total Assets
FDMT
FDMT
PLYM
PLYM
Q4 25
$566.7M
Q3 25
$424.0M
$1.6B
Q2 25
$473.6M
$1.6B
Q1 25
$515.7M
$1.4B
Q4 24
$560.4M
$1.4B
Q3 24
$604.0M
$1.5B
Q2 24
$620.1M
$1.4B
Q1 24
$629.9M
$1.4B
Debt / Equity
FDMT
FDMT
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
PLYM
PLYM
Operating Cash FlowLast quarter
$28.6M
$20.0M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
PLYM
PLYM
Q4 25
$28.6M
Q3 25
$-46.5M
$20.0M
Q2 25
$-43.4M
$23.4M
Q1 25
$-47.8M
$15.6M
Q4 24
$-134.6M
$96.1M
Q3 24
$-29.4M
$17.6M
Q2 24
$-30.2M
$19.9M
Q1 24
$-29.1M
$16.6M
Free Cash Flow
FDMT
FDMT
PLYM
PLYM
Q4 25
$28.5M
Q3 25
$-46.6M
Q2 25
$-43.4M
Q1 25
$-48.4M
Q4 24
$-138.4M
Q3 24
$-31.2M
Q2 24
$-30.6M
Q1 24
$-29.8M
FCF Margin
FDMT
FDMT
PLYM
PLYM
Q4 25
33.5%
Q3 25
-51765.6%
Q2 25
-289620.0%
Q1 25
-345635.7%
Q4 24
-13837100.0%
Q3 24
-1038966.7%
Q2 24
-611840.0%
Q1 24
-106421.4%
Capex Intensity
FDMT
FDMT
PLYM
PLYM
Q4 25
0.1%
Q3 25
101.1%
Q2 25
440.0%
Q1 25
4507.1%
Q4 24
378600.0%
Q3 24
59266.7%
Q2 24
6980.0%
Q1 24
2535.7%
Cash Conversion
FDMT
FDMT
PLYM
PLYM
Q4 25
1.47×
Q3 25
Q2 25
Q1 25
2.67×
Q4 24
0.65×
Q3 24
Q2 24
15.12×
Q1 24
2.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons